I'm trying to get a handle on a very slippery time
Post# of 148181
We have limited time and money raising opportunities at this point. Getting a partner or approval may save us but if it doesn't happen within this year, my personal timeline of this molecule being a success with Cytodyn seems to go into reverse mode. I have been an avid supporter for 4 years now and have invested way over my allotment because of Nader and possible my nature of being a chance taker in the bio market. Knowing this economy is going to continually punish companies with negative earnings going forward for possibly the next 2 years even if they have a great story, is partially my reasoning for this musing. Earnings seems to be the key and the company has to somehow make that happen. Even if it means making deals that seem fortuitous to the larger company for the time being, I think it is the way forward. Continually selling stock has kept the doors open but at some point real soon, it will make the company worthless, especially to older shareholders who can't keep putting money into lower their SP when there can be potentially a billion shares out there and an extending timeline.
I'm not raising a red flag, more of a warning shot to the mgmt...make a deal before the ship runs aground and we all scatter like roaches to the next greatest thing with our tails between our legs and a very expensive lesson.
Is this next announcement important? you bet your ass it is! The reason Cytodyn has not updated us is...they have no concrete info that will move the SP positively and know it. They understood salesman speak has worn out everyone and pure definable results are the only meter to go by. The results next week will determine to a large extent if a breath of hope is there to partner in my estimation. The molecule has many optimistic areas of research but few takers. That almost always means the large companies that are interested are waiting like vultures and will do all they can to make sure it comes within millimeters of death before swooping down to scoop it up at nothing prices. They obviously don't have confidence that the mgmt can steer the company long enough to win the war and are content to let them flounder until they die (knowing they have a partner in the FDA with their foot on our neck) and take many of us investors down with them. This intern allows their competing drugs to flourish while ours dies. It's a win win for the acquiring company. Unfortunately I have seen this in a few investments throughout my years and am starting to see the writing on the wall once again. I am hoping next week brings not only good factual results that blow away the competition but also a partnership announcement. Sorry for the long disjointed post but almost $1,000,000 invested and peanuts to show has made me active and short tempered to say the least.
Ok, I'm done for the year. Moderators, you may delete this post but I felt the need to get it out. Whew!